Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance

Edwards Lifesciences Reports Fourth Quarter Results

February 10, 2026 4:15 PM EST

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025.

Highlights and Outlook

Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 10% FY 2026 revenue outlook includes TMTT growing 35 45% to $740... More